Search research articles
Contact Us
Filters
Showing results (301-310 of 313) with videos related to
Page
of 32
Sort By:
Hematological Oncology
|
May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
Antonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Haematologica
|
June 26, 2025
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice
Anna Maria Frustaci, Andrea Galitzia, Mariano Lucignano, et al.
American Journal of Hematology
|
February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group
Yair Herishanu, Adir Shaulov, Riva Fineman, et al.
Blood Advances
|
October 24, 2025
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL
Thomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel, et al.
Haematologica
|
March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
European Journal of Haematology
|
March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients
Fortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
The Lancet. Haematology
|
August 18, 2020
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti, Chiara Cattaneo, Luca Arcaini, et al.
Blood Advances
|
January 7, 2026
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort
Enrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, et al.
Hematological Oncology
|
December 29, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study
Ernesto Vigna, Enrica Antonia Martino, Annalisa Pitino, et al.
Leukemia
|
July 11, 2020
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 313) with videos related to
Sort By:
Page
of 32
Hematological Oncology
|
May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
Antonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Haematologica
|
June 26, 2025
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice
Anna Maria Frustaci, Andrea Galitzia, Mariano Lucignano, et al.
American Journal of Hematology
|
February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group
Yair Herishanu, Adir Shaulov, Riva Fineman, et al.
Blood Advances
|
October 24, 2025
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL
Thomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel, et al.
Haematologica
|
March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
European Journal of Haematology
|
March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients
Fortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
The Lancet. Haematology
|
August 18, 2020
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti, Chiara Cattaneo, Luca Arcaini, et al.
Blood Advances
|
January 7, 2026
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort
Enrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, et al.
Hematological Oncology
|
December 29, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study
Ernesto Vigna, Enrica Antonia Martino, Annalisa Pitino, et al.
Leukemia
|
July 11, 2020
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, et al.
Page
of 32